InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,480.33
(
-0.76%
)
US TECH 100
18,712.06
(
-0.69%
)
Dow Jones
40,420.70
(
-1.03%
)
Brent Oil
80.49
(
-1.26%
)
Bitcoin
63,765.29
(
-1.29%
)
Post# of 1954
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JohnCM

Send PM Follow Ignore
Followers 698
Posts 59465
Boards Moderated 18
Alias Born 06/01/2008

JohnCM

Re: Captainandy post# 1676

Tuesday, 06/26/2018 2:09:04 AM

Tuesday, June 26, 2018 2:09:04 AM

Post# of 1954

EPIDIOLEX will be marketed in the U.S. by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals plc. As part of the approval process, EPIDIOLEX must be rescheduled from its current Schedule I before it can be made available to patients. Rescheduling is expected to occur within 90 days.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up